[
  {
    "ts": "2025-09-24T15:06:00+00:00",
    "headline": "REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug",
    "summary": "Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.",
    "url": "https://finance.yahoo.com/news/repl-stock-plunges-54-3-150600286.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0b8de271-a025-386b-b3f7-95001c152b9b",
      "content": {
        "id": "0b8de271-a025-386b-b3f7-95001c152b9b",
        "contentType": "STORY",
        "title": "REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug",
        "description": "",
        "summary": "Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.",
        "pubDate": "2025-09-24T15:06:00Z",
        "displayTime": "2025-09-24T15:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890",
          "originalWidth": 620,
          "originalHeight": 393,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/owRrQw..RZz13mqQwVBgRA--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890.cf.webp",
              "width": 620,
              "height": 393,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xvPk7PEgDBlSHxNlV1Nayw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/repl-stock-plunges-54-3-150600286.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/repl-stock-plunges-54-3-150600286.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-24T13:43:00+00:00",
    "headline": "BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study",
    "summary": "Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.",
    "url": "https://finance.yahoo.com/news/bmy-reports-positive-data-stage-134300886.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a944d53a-48a4-3fb6-8ce8-577a65c95e66",
      "content": {
        "id": "a944d53a-48a4-3fb6-8ce8-577a65c95e66",
        "contentType": "STORY",
        "title": "BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study",
        "description": "",
        "summary": "Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.",
        "pubDate": "2025-09-24T13:43:00Z",
        "displayTime": "2025-09-24T13:43:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmy-reports-positive-data-stage-134300886.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmy-reports-positive-data-stage-134300886.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-24T11:45:00+00:00",
    "headline": "The Smartest Dividend Stock to Buy With $1,000 Right Now",
    "summary": "Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.",
    "url": "https://www.fool.com/investing/2025/09/24/the-smartest-dividend-stock-to-buy-with-1000-right/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "4f398479-7061-3ec9-bd4a-63c9f8724ac1",
      "content": {
        "id": "4f398479-7061-3ec9-bd4a-63c9f8724ac1",
        "contentType": "STORY",
        "title": "The Smartest Dividend Stock to Buy With $1,000 Right Now",
        "description": "",
        "summary": "Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.",
        "pubDate": "2025-09-24T11:45:00Z",
        "displayTime": "2025-09-24T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/49b50a4f8eac7de882bb610bea79c4d1",
          "originalWidth": 1400,
          "originalHeight": 833,
          "caption": "A balance showing risk and reward.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/raZFyoVqrEVNWEls1cR79A--~B/aD04MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/49b50a4f8eac7de882bb610bea79c4d1.cf.webp",
              "width": 1400,
              "height": 833,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iDhVoW0XbKJ_vtGVrZ5g.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/49b50a4f8eac7de882bb610bea79c4d1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/09/24/the-smartest-dividend-stock-to-buy-with-1000-right/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/smartest-dividend-stock-buy-1-114500679.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-24T11:00:00+00:00",
    "headline": "SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform",
    "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and BL-M07D1, two distinct clinical programs from its antibody drug conjugate (ADC) pipeline, at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany. Iza-bren, a potentially first-in-class EGFRxHER3 bispecific ADC, is jointly developed by SystImmune and Bristol Myers Squibb under a collabora",
    "url": "https://finance.yahoo.com/news/systimmune-inc-present-clinical-data-110000915.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "fe0a88ed-ab9d-30c0-b1d5-bf47ad0d4cce",
      "content": {
        "id": "fe0a88ed-ab9d-30c0-b1d5-bf47ad0d4cce",
        "contentType": "STORY",
        "title": "SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform",
        "description": "",
        "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and BL-M07D1, two distinct clinical programs from its antibody drug conjugate (ADC) pipeline, at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany. Iza-bren, a potentially first-in-class EGFRxHER3 bispecific ADC, is jointly developed by SystImmune and Bristol Myers Squibb under a collabora",
        "pubDate": "2025-09-24T11:00:00Z",
        "displayTime": "2025-09-24T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd",
          "originalWidth": 400,
          "originalHeight": 200,
          "caption": "(PRNewsfoto/SystImmune Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9O6MLWScjve8x12UaJ5fdQ--~B/aD0yMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd.cf.webp",
              "width": 400,
              "height": 200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w3IY14xgSYxhxZXyRr5iJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/systimmune-inc-present-clinical-data-110000915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/systimmune-inc-present-clinical-data-110000915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]